Investors Find Opportunity In Tau-Targeting Biopharmas
Tau-targeting Alzheimer's candidates, though historically rejected in favor of amyloid-beta targeting ones, have gained increasing interest from investors and larger pharma companies.
Tau-targeting Alzheimer's candidates, though historically rejected in favor of amyloid-beta targeting ones, have gained increasing interest from investors and larger pharma companies.